Infectious complications of pediatric liver transplantation.
Twenty-five pediatric orthotopic liver transplantations (OLTs) performed in 22 patients at Sainte-Justine Hospital were reviewed for infections complications. One patient died within 12 hours posttransplantation and is excluded. The patients had an average age of 6.1 years (range, 1.25 to 19 years) and an average weight of 20.4 kg (range, 11 to 55 kg). Two patients (9%) were cytomegalovirus (CMV) seropositive and 9 of 19 patients (48%) were Epstein-Barr virus (EBV) seropositive preoperatively. Five of the donors (20%) were CMV seropositive. The most common indications for OLT were biliary atresia (8) and tyrosinemia (7). There were 4 deaths, for an overall mortality rate of 19%. In 3 patients, deaths were related to infection (CMV hepatitis and duodenitis with aortoduodenal fistula, adult respiratory distress syndrome [ARDS] with Streptococcus viridans pneumonia, Escherichia coli cholangitis with progressive hepatic failure). Fifteen patients (72%) had 41 major infections, most of them bacterial, during the first month posttransplantation. These include pneumonia (25%), line sepsis (17%), cholangitis (14%), and tracheitis (14%). There was only one major viral infection, a CMV hepatitis that occurred in the first month posttransplantation. Three patients had fungal infections (8%) associated with hepatic artery thrombosis and recurrent cholangitis. All three patients required retransplantation. There was only one protozoal infection (Pneumocystis carinii pneumonia) causing life-threatening respiratory failure, from which patient recovered without sequelae. Infection still remains a serious complication of OLT. Bacterial infection is common and is usually associated with technical complications. The low rate of CMV infection is related to low incidence of CMV in the donor pool and the minimal use of strong immunosuppressants.
Saint-Vil
D
D
Department of Surgery, Ste-Justine Hospital, University of Montreal, Quebec, Canada.
Luks
F I
FI
Lebel
P
P
Brandt
M L
ML
Paradis
K
K
Weber
A
A
Guay
J
J
Guttman
F M
FM
Bensoussan
A L
AL
Laberge
J M
JM
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents; D015984:Causality; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D007239:Infections / Q000209:etiology* / Q000401:mortality; D008107:Liver Diseases / Q000401:mortality; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D011292:Premedication; D012086:Reoperation; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D007166:Immunosuppressive Agents